1393813-42-7 Usage
Description
SulfaMide, N-[5-(4-bromophenyl)-6-chloro-4-pyrimidinyl]-N'-propyl-, is a synthetic intermediate with significant importance in the pharmaceutical industry. It is characterized by its unique chemical structure, which features a 4-bromophenyl group, a 6-chloro-4-pyrimidinyl group, and a propylsulfamide functional group. SulfaMide, N-[5-(4-broMophenyl)-6-chloro-4-pyriMidinyl]-N'-propylplays a crucial role in the synthesis of various drugs, particularly Macitentan, which is an orally active and potent dual endothelin receptor antagonist.
Uses
Used in Pharmaceutical Industry:
SulfaMide, N-[5-(4-bromophenyl)-6-chloro-4-pyrimidinyl]-N'-propylis used as a synthetic intermediate for the production of Macitentan (M105005). Macitentan is an orally active, potent dual endothelin receptor antagonist that is specifically designed to treat pulmonary arterial hypertension. The compound's unique structure allows it to effectively block the action of endothelin, a potent vasoconstrictor, thereby reducing the pressure in the pulmonary arteries and improving the symptoms of pulmonary arterial hypertension.
Application Reason:
The use of SulfaMide, N-[5-(4-bromophenyl)-6-chloro-4-pyrimidinyl]-N'-propylin the synthesis of Macitentan is due to its ability to provide a stable and efficient route for the production of the drug. The compound's unique chemical structure allows for the formation of the desired drug with high selectivity and yield, making it an essential component in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1393813-42-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,3,8,1 and 3 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1393813-42:
(9*1)+(8*3)+(7*9)+(6*3)+(5*8)+(4*1)+(3*3)+(2*4)+(1*2)=177
177 % 10 = 7
So 1393813-42-7 is a valid CAS Registry Number.
1393813-42-7Relevant articles and documents
Improved and single-pot process for the synthesis of macitentan, an endothelin receptor antagonist, via lithium amide-mediated nucleophilic substitution
Jagtap, Kunal M.,Niphade, Navnath C.,Gaikwad, Chandrashekhar T.,Shinde, Gorakshanath B.,Toche, Raghunath B.,Joshi, Divyesh R.,Mathad, Vijayavitthal T.
, p. 653 - 661 (2018)
Abstract: An improved, simple, efficient, and telescoped synthesis of macitentan, an endothelin receptor antagonist, starting from 5-(4-bromophenyl)-4,6-dichloropyrimidine in an overall yield of around 62% is described. Graphical abstract: [Figure not available: see fulltext.].
A Novel Synthesis of Macitentan, an Endothelin Receptor Antagonist
Nami, Majid,Sovari, Sara Nasiri,Haghighatnia, Yaghoub,Dabiri, Minoo,Salehi, Peyman
, p. 258 - 264 (2017/06/09)
-
PROCESS FOR PREPARATION OF MACITENTAN
-
Page/Page column 12; 13, (2017/12/18)
The present invention relates to a process for the preparation of N-[5-(4-Bromophenyl)- 6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'propylsulfamide or Macitentan of Formula (I). The present invention further relates to a process for the preparation highly pure N-[5- (4-Bromophenyl)-6- [2- [(5 -bromo-2-pyrimidinyl)oxy]ethoxy] -4-pyrimidinyl] - N'propylsulfamide or Macitentan of Formula (I). Said substantially pure Macitentan is useful in the preparation of pharmaceutical composition for the treatment of cardiac disorders.
